Logo.jpg
CELSION CORPORATION ANNOUNCES CLOSING OF $35 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK PRICED AT-THE-MARKET UNDER NASDAQ RULES
January 26, 2021 17:00 ET | Celsion CORP
Lawrenceville, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced registered...
Logo.jpg
CELSION CORPORATION ANNOUNCES $35 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
January 22, 2021 08:40 ET | Celsion CORP
LAWRENCEVILLE, NJ, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional...
LOGO.jpg
FINAL CLSN DEADLINE TODAY: ROSEN, RESPECTED INVESTOR COUNSEL, Reminds Celsion Corporation Investors of Important Tuesday Deadline in Securities Class Action – CLSN
December 29, 2020 09:10 ET | The Rosen Law Firm PA
NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BMW, Zosano Pharma, Celsion, and Citigroup and Encourages Investors to Contact the Firm
December 16, 2020 17:00 ET | Bragar Eagel & Squire
NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BMW, Zosano Pharma, Celsion, and Citigroup and Encourages Investors to Contact the Firm
December 09, 2020 17:00 ET | Bragar Eagel & Squire
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
LOGO.jpg
ROSEN, RESPECTED INVESTOR COUNSEL, Reminds Celsion Corporation Investors of Important December 29 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – CLSN
December 03, 2020 17:17 ET | The Rosen Law Firm PA
NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BMW, Zosano Pharma, Celsion, and Citigroup and Encourages Investors to Contact the Firm
December 02, 2020 19:00 ET | Bragar Eagel & Squire
NEW YORK,, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Celsion, Citigroup, Raytheon, Intercept Pharmaceuticals and Encourages Investors to Contact the Firm
November 24, 2020 19:00 ET | Bragar Eagel & Squire
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zosano Pharma, Celsion, Citigroup, and Raytheon and Encourages Investors to Contact the Firm
November 18, 2020 20:00 ET | Bragar Eagel & Squire
NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Logo.jpg
Celsion Corporation Reports Third Quarter 2020 Financial Results and Provides Business Update
November 16, 2020 08:30 ET | Celsion CORP
        Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer Continues Following Patients for Overall Survival in Phase III OPTIMA Study Conference Call Begins Today at 11:00...